Abstract
Protein-protein interactions play a crucial role in numerous vital cell functions. However proteinprotein interactions are also responsible for pathological formation of protein aggregates, which determine the development of several diseases. The key role of protein-protein interactions for manifestation of numerous cell functions attracts much attention to protein complexes as perspective drug targets. So design or discovery of small molecules that would regulate protein-protein interactions represents great pharmacological interest. The recent progress in understanding of mechanism protein-protein interaction, including role of flexibility of protein-protein interfaces, thermodynamic of complex formation, discovery of small molecules modifying protein-protein interactions, the advantages and limitation of protein-protein inhibitors as potential drugs are discussed in this review.
Keywords: Protein-protein interaction, inhibitors, target, dimerization, drug, flexibility, allosteric inhibition
Current Computer-Aided Drug Design
Title: Inhibitors of Protein-Protein Interactions as Potential Drugs
Volume: 3 Issue: 1
Author(s): Alexander V. Veselovsky and Alexander I. Archakov
Affiliation:
Keywords: Protein-protein interaction, inhibitors, target, dimerization, drug, flexibility, allosteric inhibition
Abstract: Protein-protein interactions play a crucial role in numerous vital cell functions. However proteinprotein interactions are also responsible for pathological formation of protein aggregates, which determine the development of several diseases. The key role of protein-protein interactions for manifestation of numerous cell functions attracts much attention to protein complexes as perspective drug targets. So design or discovery of small molecules that would regulate protein-protein interactions represents great pharmacological interest. The recent progress in understanding of mechanism protein-protein interaction, including role of flexibility of protein-protein interfaces, thermodynamic of complex formation, discovery of small molecules modifying protein-protein interactions, the advantages and limitation of protein-protein inhibitors as potential drugs are discussed in this review.
Export Options
About this article
Cite this article as:
Veselovsky V. Alexander and Archakov I. Alexander, Inhibitors of Protein-Protein Interactions as Potential Drugs, Current Computer-Aided Drug Design 2007; 3 (1) . https://dx.doi.org/10.2174/157340907780058754
DOI https://dx.doi.org/10.2174/157340907780058754 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Modulation of Endoplasmic Reticulum Stress: An Opportunity to Prevent Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders
Current Protein & Peptide Science Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Snake Venom: From Deadly Toxins to Life-saving Therapeutics
Current Medicinal Chemistry Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Exploring the Mechanism of Lingzhu San in Treating Febrile Seizures by Using Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Metallothionein I+II Expression as an Early Sign of Chronic Relapsing Experimental Autoimmune Encephalomyelitis in Rats
Current Aging Science Minocycline and Cytoprotection: Shedding New Light on a Shadowy Controversy
Current Drug Delivery Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development)
Current Pharmaceutical Design Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness
Current Neurovascular Research Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists
Current Alzheimer Research P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms
Current Neuropharmacology Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Current Gene Therapy